Chiron Proleukin metastatic melanoma lower-dose postmarketing studies urged by FDA advisory cmte..
Executive Summary
CHIRON PROLEUKIN LOWER DOSE STUDIES IN METASTATIC MELANOMA should be conducted post-approval, with the agent alone or in combination with interferon alfa or chemotherapeutic drugs, FDA's Oncologic Drugs Advisory Committee suggested Dec. 19. Reduced Proleukin (aldesleukin, interleukin-2) doses could decrease toxicity and lower the cost of treatment, committee member Derek Raghavan, MD/PhD, Roswell Park Cancer Institute, maintained. BLA 97-0501 was accepted for priority review by FDA April 10. Proleukin has been approved since 1992 for renal cell carcinoma.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth